27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Following consultations with the FDA, ChemoCentryx Inc (NASDAQ:CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis addressing concerns raised during the FDA Advisory Committee meeting in May.
- The FDA has indicated that the filing constitutes a significant amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7.
- The application is primarily based on data from the Phase 3 ADVOCATE trial of avacopan.
- In May, the FDA's Arthritis Advisory Committee voted 9-9 on whether the efficacy data support avacopan approval, 10-8 that the safety profile of avacopan is adequate, and 10-8 that the benefit-risk profile is sufficient.
- ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels.
- Price Action: CCXI shares are up 8.9% at $14.35 during the premarket session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!